CA2834368C - Use of fk506 for the treatment of pulmonary arterial hypertension - Google Patents

Use of fk506 for the treatment of pulmonary arterial hypertension Download PDF

Info

Publication number
CA2834368C
CA2834368C CA2834368A CA2834368A CA2834368C CA 2834368 C CA2834368 C CA 2834368C CA 2834368 A CA2834368 A CA 2834368A CA 2834368 A CA2834368 A CA 2834368A CA 2834368 C CA2834368 C CA 2834368C
Authority
CA
Canada
Prior art keywords
mammal
pulmonary arterial
arterial hypertension
dosage
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2834368A
Other languages
English (en)
French (fr)
Other versions
CA2834368A1 (en
Inventor
Edda SPIEKERKOETTER
Marlene Rabinovitch
Philip A. Beachy
David Solow-Cordero
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Leland Stanford Junior University
Original Assignee
Leland Stanford Junior University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leland Stanford Junior University filed Critical Leland Stanford Junior University
Publication of CA2834368A1 publication Critical patent/CA2834368A1/en
Application granted granted Critical
Publication of CA2834368C publication Critical patent/CA2834368C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5041—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects involving analysis of members of signalling pathways
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Toxicology (AREA)
  • Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CA2834368A 2011-05-02 2012-04-30 Use of fk506 for the treatment of pulmonary arterial hypertension Active CA2834368C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161481317P 2011-05-02 2011-05-02
US61/481,317 2011-05-02
PCT/US2012/035793 WO2012151153A1 (en) 2011-05-02 2012-04-30 Use of fk506 for the treatment of pulmonary arterial hypertension

Publications (2)

Publication Number Publication Date
CA2834368A1 CA2834368A1 (en) 2012-11-08
CA2834368C true CA2834368C (en) 2020-02-18

Family

ID=47108011

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2834368A Active CA2834368C (en) 2011-05-02 2012-04-30 Use of fk506 for the treatment of pulmonary arterial hypertension

Country Status (19)

Country Link
US (6) US9474745B2 (enExample)
EP (3) EP4279130A3 (enExample)
JP (1) JP6177765B2 (enExample)
AU (2) AU2012250974B9 (enExample)
CA (1) CA2834368C (enExample)
CY (1) CY1123900T1 (enExample)
DK (2) DK2704711T3 (enExample)
ES (2) ES2856173T3 (enExample)
FI (1) FI3821891T3 (enExample)
HR (1) HRP20210245T1 (enExample)
HU (1) HUE053229T2 (enExample)
LT (1) LT2704711T (enExample)
PL (1) PL2704711T3 (enExample)
PT (2) PT3821891T (enExample)
RS (1) RS61480B1 (enExample)
SI (1) SI2704711T1 (enExample)
SM (1) SMT202100085T1 (enExample)
WO (1) WO2012151153A1 (enExample)
ZA (1) ZA201307905B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2704711T3 (da) 2011-05-02 2021-02-22 Univ Leland Stanford Junior Anvendelse af fk506 til behandlingen af pulmonal arteriel hypertension
AU2016207046B2 (en) * 2015-01-13 2021-04-01 Vivus Llc Combination therapy for pulmonary hypertension
MX2017014301A (es) * 2015-05-08 2018-03-23 Vivus Inc Composiciones y metodos para el tratamiento o prevencion de hipertension pulmonar.
CN108070566A (zh) * 2015-08-05 2018-05-25 中国医学科学院基础医学研究所 肺动脉高压治疗药物的干细胞筛选模型及应用
ES2683921B1 (es) * 2017-03-28 2019-04-22 Univ Vigo Método para la determinación del pronóstico en sujetos diagnosticados con hipertensión arterial pulmonar
EP3624821A4 (en) * 2017-05-19 2021-01-20 The Board of Trustees of the Leland Stanford Junior University ENZASTAURIN AND FRAGILE HISTIDINTRIAD (FHIT) - ENHANCING AGENTS FOR TREATMENT OF PULMONAL HYPERTENSION
EP3773571A1 (en) 2018-03-28 2021-02-17 Georg-August-Universitaet Goettingen Stiftung Oeffentlichen Rechts, Universitaetsmedizin Prevention or treatment of chronic organ injury

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6489335B2 (en) * 2000-02-18 2002-12-03 Gholam A. Peyman Treatment of ocular disease
US20050119330A1 (en) 2003-03-17 2005-06-02 Kao Peter N. Use of antiproliferative agents in the treatment and prevention of pulmonary proliferative vascular diseases
AU2007230964B2 (en) 2006-03-23 2012-07-19 Santen Pharmaceutical Co., Ltd. Formulations and methods for vascular permeability-related diseases or conditions
FR2936060B1 (fr) * 2008-09-17 2010-11-19 Assist Publ Hopitaux De Paris Procede de diagnostic d'une sclerodermie systemique ou d'une hypertension arterielle pulmonaire.
MX2011004284A (es) * 2008-10-22 2011-06-21 Sam Amer & Co Inc Metodo para tratar la hipertension arterial pulmonar.
DK2704711T3 (da) 2011-05-02 2021-02-22 Univ Leland Stanford Junior Anvendelse af fk506 til behandlingen af pulmonal arteriel hypertension

Also Published As

Publication number Publication date
SMT202100085T1 (it) 2021-05-07
ES2856173T3 (es) 2021-09-27
WO2012151153A1 (en) 2012-11-08
EP4279130A2 (en) 2023-11-22
LT2704711T (lt) 2021-04-26
EP2704711A4 (en) 2014-11-19
JP2014513121A (ja) 2014-05-29
HUE053229T2 (hu) 2021-06-28
US9474745B2 (en) 2016-10-25
EP3821891A1 (en) 2021-05-19
DK2704711T3 (da) 2021-02-22
CA2834368A1 (en) 2012-11-08
HRP20210245T1 (hr) 2021-04-02
AU2012250974B2 (en) 2017-05-04
US20170007585A1 (en) 2017-01-12
ZA201307905B (en) 2015-05-27
US20180185340A1 (en) 2018-07-05
US20220184042A1 (en) 2022-06-16
CY1123900T1 (el) 2022-05-27
EP3821891B1 (en) 2023-06-07
JP6177765B2 (ja) 2017-08-09
US20140135358A1 (en) 2014-05-15
ES2954905T3 (es) 2023-11-27
US12521379B2 (en) 2026-01-13
SI2704711T1 (sl) 2021-04-30
PL2704711T3 (pl) 2021-07-05
US20230404982A1 (en) 2023-12-21
AU2017210583A1 (en) 2017-08-24
DK3821891T3 (da) 2023-09-04
FI3821891T3 (fi) 2023-08-24
AU2012250974A1 (en) 2013-11-14
AU2017210583B2 (en) 2019-02-07
PT3821891T (pt) 2023-08-31
EP2704711B1 (en) 2020-12-02
US20190091208A1 (en) 2019-03-28
AU2012250974B9 (en) 2017-05-18
RS61480B1 (sr) 2021-03-31
EP2704711A1 (en) 2014-03-12
EP4279130A3 (en) 2024-02-21
PT2704711T (pt) 2021-03-02

Similar Documents

Publication Publication Date Title
US12521379B2 (en) Use of FK506 for the treatment of pulmonary arterial hypertension
Augustine et al. Use of sirolimus in solid organ transplantation
Stallone et al. Rapamycin for treatment of chronic allograft nephropathy in renal transplant patients
JP7494277B2 (ja) ダパグリフロジンを用いて、駆出率が低下した心不全を治療する方法
Vincenti et al. Results of an international, randomized trial comparing glucose metabolism disorders and outcome with cyclosporine versus tacrolimus
Reichenspurner Overview of tacrolimus-based immunosuppression after heart or lung transplantation
US20140113930A1 (en) Therapeutic combination for cancer treatment
EP4146202A1 (en) Method of treating a patient infected with a coronavirus with nezulcitinib
Valantine Neoral use in the cardiac transplant recipient
AU2010234360A1 (en) Methods and compositions of PI-3 kinase inhibitors for treating fibrosis
KR20050106038A (ko) 심장질환 및 신장질환의 치료를 위한 아데노신 ａ1 수용체길항제
JP2018502126A (ja) 肺高血圧症のための併用療法
Doyle et al. RAD in stable lung and heart/lung transplant recipients: safety, tolerability, pharmacokinetics, and impact of cystic fibrosis
KR20250105629A (ko) 유형 i 당뇨병에서의 만성 신장 질환의 치료
Mukherjee et al. Immunosuppression in liver transplantation
Lake Immunosuppressive drugs and novel strategies to prevent acute and chronic allograft rejection
Kane et al. Present and future treatment strategies for pulmonary arterial hypertension: focus on phosphodiesterase-5 inhibitors
Tönshoff et al. Renal transplantation: Immunosuppression and managing allograft rejection
WO2024243700A1 (en) Methods for treating lupus nephritis with voclosporin
ZAZA et al. 18 mTOR Inhibitors: Sirolimus and
Culos et al. Immunosuppressive agents and monitoring in long‐term survivors
Scholten et al. Pharmacotherapeutic approach to prevent or treat chronic allograft nephropathy

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20170427

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 13TH ANNIV.) - STANDARD

Year of fee payment: 13

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250321

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250321